top of page

Frost lab interviewed by KENS5

The Frost lab was interviewed by San Antonio news station KENS5 to comment on the results from Biogen's phase 1b clinical trials with the drug Aducanumab, a monoclonal antibody that targets Amyloid beta aggregates.

The Frost lab was not involved in the study.

Alzforum has a nice write-up about Aducanumab:

Stay up to date on the progress of Aducanumab clinical trials:

bottom of page